What is the Origin of Sermorelin CJC 1295 Therapy?

This therapy originated from decades of research into the hypothalamic-pituitary axis and the neuroendocrine regulation of Growth Hormone secretion. Sermorelin is a synthetic version of the naturally occurring GHRH fragment, while CJC 1295 is a synthetic GHRH analog with a Drug Affinity Complex (DAC) modification that significantly extends its half-life. The combination therapy is rooted in the desire to provide a more physiological and sustained GH secretagogue effect.

What is the Mechanism of Sermorelin CJC 1295 Therapy?

Both peptides bind to the GHRH receptors on the somatotroph cells of the anterior pituitary gland, stimulating the synthesis and release of Growth Hormone. CJC 1295's extended half-life, due to its conjugation with albumin, provides a sustained GHRH-like signal, leading to a prolonged and more consistent release of GH. This mechanism promotes the natural, pulsatile release pattern of GH, which then acts on target tissues, including the liver, to produce IGF-1, mediating most of the anabolic and regenerative effects.

Sermorelin CJC 1295 Therapy ∞ Area

Sermorelin CJC 1295 Therapy

Meaning

Sermorelin CJC 1295 Therapy is a combination regimen utilizing two synthetic peptides, Sermorelin and CJC 1295, that function as Growth Hormone-Releasing Hormone (GHRH) analogs to stimulate the pituitary gland’s pulsatile secretion of endogenous Growth Hormone (GH). This therapeutic approach aims to restore more youthful, physiological levels of GH and its downstream mediator, Insulin-like Growth Factor 1 (IGF-1), without introducing exogenous GH itself. The clinical application is focused on improving body composition, enhancing cellular repair, and supporting overall vitality.